Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy

by Fahmin Basher, Payal Dhar, Xin Wang, Derek A. Wainwright, Bin Zhang, Jeffrey Sosman, Zhe Ji, Jennifer D. Wu
Published 2020-06-01

Past, Current, and Future of Immunotherapies for Prostate Cancer

by Adeline N. Boettcher, Ahmed Usman, Alicia Morgans, David J. VanderWeele, Jeffrey Sosman, Jennifer D. Wu, Jennifer D. Wu
Published 2019-09-01

CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy

by Siqi Chen, Jie Fan, Minghui Zhang, Lei Qin, Donye Dominguez, Alan Long, Gaoxiang Wang, Renqiang Ma, Huabin Li, Yi Zhang, Deyu Fang, Jeffrey Sosman, Bin Zhang
Published 2019-01-01

312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition

by Gary Cohen, Omid Hamid, Lawrence Flaherty, Henry Koon, Jeffrey Sosman, David Minor, Zeynep Eroglu, John Kirkwood, F Stephen Hodi, Donald Lawrence, Ni Kang, Sandra Lee, Laura Hutchins, Harriett Kluger, Kari Kendra, Carrie Lee, Mark Albertini, Teresa Petrella, Howard Striecher, Vernon Sondak
Published 2020-11-01

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials.

by Christine M Lovly, Kimberly Brown Dahlman, Laurel E Fohn, Zengliu Su, Dora Dias-Santagata, Donna J Hicks, Donald Hucks, Elizabeth Berry, Charles Terry, MarKeesa Duke, Yingjun Su, Tammy Sobolik-Delmaire, Ann Richmond, Mark C Kelley, Cindy L Vnencak-Jones, A John Iafrate, Jeffrey Sosman, William Pao
Published 2012-01-01